Department of Thoracic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Kaohsiung J Med Sci. 2021 May;37(5):411-418. doi: 10.1002/kjm2.12339. Epub 2020 Dec 19.
Promising cancer treatment requires the assistant of drug delivery systems (DDS) with the aim to increase the accumulation of drugs in tumor tissue. Herein, a hybrid DDS was successfully developed to integrate chondroitin sulfate (CS) and calcium carbonate (CC) in to one system. Anticancer drug adriamycin (Adr) was preloaded into CC nanoparticles to obtain Adr-loaded CC nanoparticles (CC/Adr). The resulted CS-CC/Adr nanoparticles as a biocompatible DDS was able to specifically target cancer cells to enhance the chemotherapy of lung cancer due to the surface modification of CS. Intracellular uptake as well as in vivo imaging results revealed the obtained CS-CC/Adr nanoparticles (size of ~100 nm) showed CS mediated tumor specific accumulation into A549 and LLC cells than unmodified CC/Adr, in which the CD44 receptor might be involved, which finally resulted in stronger anticancer capability than Adr or CC/Adr. As a result, CS-CC/Adr nanoparticles could be further extended to clinical administration in our future works.
有前途的癌症治疗需要药物传递系统（DDS）的辅助，目的是增加药物在肿瘤组织中的积累。在此，成功开发了一种混合 DDS，将硫酸软骨素（CS）和碳酸钙（CC）集成到一个系统中。将抗癌药物阿霉素（Adr）预先加载到 CC 纳米粒子中，得到负载阿霉素的 CC 纳米粒子（CC/Adr）。所得的 CS-CC/Adr 纳米粒子作为一种生物相容性 DDS，由于 CS 的表面修饰，能够特异性靶向癌细胞，增强肺癌的化疗效果。细胞内摄取和体内成像结果表明，所得的 CS-CC/Adr 纳米粒子（大小约为 100nm）表现出 CS 介导的肿瘤特异性积累到 A549 和 LLC 细胞中，而不是未修饰的 CC/Adr，其中 CD44 受体可能参与其中，最终导致比阿霉素或 CC/Adr 更强的抗癌能力。因此，CS-CC/Adr 纳米粒子在未来的工作中可以进一步扩展到临床给药。
